Phase 2 N=12 Aflibercept Injection for Proliferative Diabetic Retinopathy
Vitreous Hemorrhage
Primary: Rate of Resolved Post-operative Vitreous Hemorrhage. — 6; 5 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=394 Prompt Panretinal Photocoagulation Versus Ranibizumab+Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
Proliferative Diabetic Retinopathy
Primary: Mean Change in Visual Acuity From Baseline — 2.8; 0.2 letters
Phase 3 N=689 Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy
Proliferative Diabetic Retinopathy
Primary: Change From Baseline in Best-corrected Visual Acuity (BCVA) at Week 54 for the Study Eye — 0.2; -4.2 Letters Read — p=<0.001
Phase 3 N=345 Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy
Proliferative Diabetic Retinopathy · Diabetic Macular Edema
Primary: Change in Electronic Early Treatment Diabetic Retinopathy Study Visual Acuity Letter Score From Baseline to 14 Weeks — -4; 1; 2 Letter Score — p=<.001
N/A N=19 Avastin for PDR (Proliferative Diabetic Retinopathy)
Retinal Detachment · Diabetic Retinopathy
Primary: The Effect of an Anti-VEGF (Vascular Endothelial Growth Factor) Agent, Bevacizumab, on Levels of Vitreous and Aqueous Growth Factor Levels (pg/mL) in Eyes With Traction…
Phase 4 N=112 Conbercept Injection in Treatment of Severe Proliferative Diabetic Retinopathy
Proliferative Diabetic Retinopathy · Tractional Retinal Detachment
Primary: Best-corrected Visual Acuity — 1.25; 1.29; 1.16 LogMAR
N/A N=900 Detection and Classification of Diabetic Retinopathy From Posterior Pole Images With A Deep Learning Model
Diabetic Retinopathy · Diabetic Eye Problems · Diabetic Macular Edema
Primary: Sensitivity(mtmDR) — 90.48; 95.65; 95.19 percentage of true positives
Phase 3 N=205 Anti-VEGF vs. Prompt Vitrectomy for VH From PDR
Proliferative Diabetic Retinopathy · Vitreous Hemorrhage
Primary: E-ETDRS Visual Acuity Letter Score (Area Under the Curve From Baseline) — 59.3; 63.0 units on a scale
Phase 2 N=108 Multicenter 12 Months Clinical Study to Evaluate Efficacy and Safety of Ranibizumab Alone or in Combination With Laser Photocoagulation vs. Laser Photocoagulation Alone in Proliferative Diabetic Retinopathy (PRIDE)
Proliferative Diabetic Retinopathy (PDR)
Primary: Change From Baseline in Area of Neovascularizations (NVs) at End of Core Study (EOCS) — -4.6; -0.9; -1.7 square millimeters — p=0.0344
Phase 3 N=261 Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy (N)
Vitreous Hemorrhage · Proliferative Diabetic Retinopathy
Primary: Treatment or "Failure" Defined as Vitrectomy — 12; 17 percentage of participants — p=0.37
Phase 2 N=43 Intravitreal Aflibercept for Retinal Non-Perfusion in Proliferative Diabetic Retinopathy
Proliferative Diabetic Retinopathy
Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 — 0; 0; 0; 0 Participants
N/A N=27 Micropulse for Suppression of Diabetic Macular Edema
Diabetic Macular Edema
Primary: Percentage of Subjects With Vision Loss to 20/40 or Worse — 5; 3 Eyes — p=.76
Phase 2 N=8 Ranibizumab for Treatment of Persistent Diabetic Neovascularization Assessed by Wide-Field Imaging
Proliferative Diabetic Retinopathy
Primary: The Mean Percentage Change of the Area of the Patient's Neovascularization as Measured in Pixels by Optomap FA (Fluorescein Angiography) — -83.8; 52.6; 11.3; 55.4…
Phase 4 N=112 Isotretinoin for Proliferative Vitreoretinopathy
Proliferative Vitreoretinopathy
Primary: Rate of Retinal Attachment — 50; 42 Participants
Phase 3 N=399 Anti-VEGF Treatment for Prevention of PDR/DME
Diabetic Retinopathy · Diabetic Macular Edema
Primary: Development of PDR and/or DME (Whichever Came First) — 27; 75 Eyes
N/A N=900 A Multi-center Study to Evaluate Performance of an Automated Device for the Detection of Diabetic Retinopathy
Diabetic Retinopathy
Primary: Sensitivity Corrected for Enrichment — 87.2 percentage of true positives
Phase 2 N=24 Study to Evaluate Effects of Emixustat Hydrochloride in Subjects With Proliferative Diabetic Retinopathy
Proliferative Diabetic Retinopathy
Primary: Change in Aqueous Humor Concentration of the Following Biomarkers:IL-6, IL-8, IP-10, PDGF-AA, TGFβ-1, MCP-1, IL-1β, and VEGF, to be Reported in pg/mL Values — 45.6; 4.9…
Phase 3 N=174 A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm
Diabetic Retinopathy
Primary: Percentage of Participants With a ≥2-Step Improvement From Baseline on the Early Treatment Diabetic Retinopathy Study-Diabetic Retinopathy Severity Scale (ETDRS-DRSS) at…
Phase 2 N=109 Non-proliferative Diabetic Retinopathy Treated With Runcaciguat
Diabetic Retinopathy
Primary: Percentage of Participants With Improvement in DRSS by ≥ 2 Steps at 48 Weeks of Treatment in the Study Eye — 0.0; 1.9 percentage of participants
Phase 4 N=69 Prospective Randomized Controlled Study of Intravitreal Injection of Bevacizumab for Proliferative Diabetic Retinopathy
Proliferative Diabetic Retinopathy · Diabetic Traction Retinal Detachment · Vitreous Hemorrhage
Primary: Reoperation — 1; 7 participants — p=0.033
Phase 2 N=30 Evaluation of Doxycycline Verses Placebo for the Treatment of Severe Nonproliferative or Mild or Moderate Proliferative Diabetic Retinopathy
Diabetic Retinopathy
Primary: Change in Dark Adaptation, Rod Intercept — 0.3; -0.3 minutes — p=.70
Phase 4 N=72 Pegaptanib for Retinal Edema Secondary to Diabetic Vascular Disease(Preserve) Study
Diabetic Macular Edema
Primary: Proportion of Subjects Who Gain Two or More Lines in Best Corrected Visual Acuity(BCVA) Score in the Study Eye Compared With Baseline. — 3; 18 participants
Phase 4 N=25 Effects of Intravitreal Ranibizumab for Macular Edema With Nonproliferative Diabetic Retinopathy
Nonproliferative Diabetic Retinopathy
Primary: The Best Corrected Visual Acuity (BCVA) — 67.6; 76.36 letters — p=<0.0001
Phase 2 N=20 Diabetic Macular Edema Treated With Ozurdex (DMEO)
Diabetic Macular Edema
Primary: Correlation Between Change in Level of Propermeability Factors With Change in Edema After Treatment With a Dexamethasone Implant or Anti-VEGF Agent — 0.47; 0.059; 0.45…
Phase 2 N=79 A Study That Tests BI 1467335 in Patients With Diabetic Eye Disease (Diabetic Retinopathy). It Looks at the Way BI 1467335 is Taken up, the Effects it Has, and How Well it is Tolerated.
Diabetic Retinopathy
Primary: Percentage of Participants With Any Ocular Adverse Events Over the On-treatment Period — 35.0; 23.1 Percentage of participants
Phase 2 N=296 Bevacizumab Against Recurrent Retinal Detachment
Retinal Detachment · Proliferative Vitreoretinopathy
Primary: Number of Participants (or Chart Reviews) With Complete Success of Primary Vitrectomy Surgery — 92; 169 Participants
Phase 3 N=402 Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR)
Nonproliferative Diabetic Retinopathy
Primary: Percentage of Participants Who Improved by ≥2 Steps From Baseline in the Diabetic Retinopathy Disease Severity Scale (DRSS) Score at Week 24 in the Combined 2Q16 and 2Q8…
N/A N=45 Dyslipidemia and Diabetic Retinopathy
Diabetic Retinopathy · Dyslipidemia
Primary: Increase in Acid Sphingomyelinase (ASM) Expression and Activity in Bone Marrow-derived Endothelial Progenitor Cells (EPCs) — 0.2; 0.5 nM/hr
Phase 2 N=77 Study of EYP-1901 in Patients With Nonproliferative Diabetic Retinopathy (NPDR)
Nonproliferative Diabetic Retinopathy
Primary: Percentage of Subjects Improved >=2 Steps From Baseline in the DRSS Score at Week 36 — 5.0; 0; 4.8 percentage of subjects
Phase 2 N=22 Ranibizumab and Peripheral Scatter Laser in Patients With Diabetic Macular Edema and Peripheral Nonperfusion
Diabetic Macular Edema
Primary: Mean Change in Best Corrected Visual Acuity (BCVA), as Assessed by the Number of Letters Read Correctly on the ETDRS Eye Chart at a Starting Test Distance of 4 Meters…